<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491985</url>
  </required_header>
  <id_info>
    <org_study_id>GPA04</org_study_id>
    <nct_id>NCT00491985</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      This is an open, randomized, multicenter clinical trial.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  To describe the safety profiles during the 21 days following each primary and booster&#xD;
           injection.&#xD;
&#xD;
        -  To describe the immune response 21 days after each primary and booster injection of each&#xD;
           formulation.&#xD;
&#xD;
        -  To describe the antibody persistence after the first vaccination&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To describe safety following administration of A/H5N1 inactivated split virion pandemic influenza vaccine.</measure>
    <time_frame>21 Days post-vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Influenza</condition>
  <condition>Orthomyxoviridae Infections</condition>
  <condition>Influenza A Virus Infection</condition>
  <arm_group>
    <arm_group_label>Study Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 9 to 17 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 3 to 8 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 6 to 35 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1 Inactivated, split-virion pandemic influenza vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Study Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1 Inactivated, split virion pandemic influenza vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Study Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1 Inactivated, split virion pandemic influenza vaccine</intervention_name>
    <description>0.25 mL, Intramuscular</description>
    <arm_group_label>Study Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
        All subjects:&#xD;
&#xD;
          -  Able to attend all scheduled visits and to comply with all trial procedures.&#xD;
&#xD;
        Children/Adolescents aged ≥ 2 years to &lt; 18 years:&#xD;
&#xD;
          -  Aged ≥ 2 years to &lt; 18 years on the day of inclusion.&#xD;
&#xD;
          -  Informed Consent Form signed by one parent or another legal representative and by an&#xD;
             independent witness if the parent/legal representative is illiterate.&#xD;
&#xD;
          -  For a female, inability to bear a child or negative urine pregnancy test (as&#xD;
             applicable).&#xD;
&#xD;
          -  For a female of child-bearing potential, use of an effective method of contraception&#xD;
             or abstinence for at least 4 weeks prior to the first vaccination and at least 4 weeks&#xD;
             after the last vaccination (as applicable).&#xD;
&#xD;
        Infants/toddlers aged ≥ 6 months to &lt; 2 years:&#xD;
&#xD;
          -  Aged ≥ 6 months to &lt; 2 years on the day of inclusion.&#xD;
&#xD;
          -  Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2 kg.&#xD;
&#xD;
          -  Informed Consent Form signed by one parent/legally acceptable representative and an&#xD;
             independent witness if the parent/legally acceptable representative is illiterate.&#xD;
&#xD;
          -  Subject who completed vaccination according to the national immunization schedule.&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
        All subjects:&#xD;
&#xD;
          -  Participation in another clinical trial in the 4 weeks preceding the first trial&#xD;
             vaccination.&#xD;
&#xD;
          -  Planned participation in another clinical trial during the present trial period.&#xD;
&#xD;
          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer&#xD;
             chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic&#xD;
             corticosteroid therapy.&#xD;
&#xD;
          -  Systemic hypersensitivity to any of the vaccine components or history of life&#xD;
             threatening reaction to the trial vaccine or a vaccine containing the same substances&#xD;
             (egg proteins, chick proteins, thimerosal, aluminum, neomycin, formaldehyde, and&#xD;
             octoxinol 9).&#xD;
&#xD;
          -  Chronic illness at a stage that could interfere with trial conduct or completion.&#xD;
&#xD;
          -  Blood or blood-derived products received in the past 3 months.&#xD;
&#xD;
          -  Any vaccination in the 4 weeks preceding the first trial vaccination.&#xD;
&#xD;
          -  Vaccination planned in the 4 weeks following any trial vaccination.&#xD;
&#xD;
          -  History of the H5N1 infection (confirmed either clinically, serologically or&#xD;
             virologically).&#xD;
&#xD;
          -  Known HIV, Hepatitis B (HBsAg) or Hepatitis C seropositivity.&#xD;
&#xD;
          -  Previous vaccination with an avian flu vaccine.&#xD;
&#xD;
          -  Subject at high risk of the H5N1 infection during the trial.&#xD;
&#xD;
          -  Thrombocytopenia or bleeding disorder contraindicating IM vaccination.&#xD;
&#xD;
          -  Febrile illness (rectal equivalent temperature ≥ 38.0°C) on the day of inclusion.&#xD;
&#xD;
        Children/Adolescents aged ≥ 2 years to &lt; 18 years:&#xD;
&#xD;
          -  Breast-feeding mothers.&#xD;
&#xD;
          -  Current alcohol abuse or drug addiction that may interfere with the subject's ability&#xD;
             to comply with trial procedures (if applicable, depending on the subject's age).&#xD;
&#xD;
        Infants/toddlers aged ≥ 6 months to &lt; 2 years:&#xD;
&#xD;
          -  History of seizures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>June 26, 2007</study_first_submitted>
  <study_first_submitted_qc>June 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza A/H5N1 Virus</keyword>
  <keyword>Influenza Pandemic</keyword>
  <keyword>Orthomyxoviridae Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Orthomyxoviridae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

